TNFerade™ Plus Chemo/Radiation/Surgery for Rectal Cancer
This study has been completed.
Sponsor:
GenVec
Information provided by:
GenVec
ClinicalTrials.gov Identifier:
NCT00137878
First received: August 26, 2005
Last updated: February 22, 2012
Last verified: May 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if the addition of TNFerade™ to pre-operative chemoradiotherapy increases the number of pathologic complete responses when compared to pre-operative chemoradiotherapy alone as assessed following complete surgical resection of primary rectal cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Rectal Cancer |
Drug: TNFerade™ |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Primary Purpose: Treatment |
| Official Title: | A Phase II Randomized Trial Comparing TNFerade™ Biologic With Capecitabine and Radiation Therapy Followed by Surgical Resection Versus Capecitabine and Radiation Therapy Followed by Surgical Resection for the Treatment of Rectal Cancer |
Resource links provided by NLM:
Further study details as provided by GenVec:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- All patients who have biopsy proven T3 or T4 rectal cancer which is confined to the primary tumor site with or without regional lymph node involvement
- Patients must be willing to return for follow-up
- Patients must be able to give and sign informed consent
- Patients must be suitable candidates for surgical resection post-chemoradiation, i.e. no history of severe congestive heart failure or severe pulmonary disease
- Life expectancy > 6 months
Exclusion Criteria:
- Patients with evidence of distant metastatic disease
- Any of the following hematologic abnormalities: hemoglobin (HGB) < 8.0 gm/dL unable to be corrected with a transfusion; absolute neutrophil count (ANC) < 1500 cells/mm3; platelets < 100,000/mm3; activated partial thromboplastin time (APTT) ratio or International Normalized Ratio (INR) > 1.5 (except in patients who are therapeutically anticoagulated for non-related medical conditions such as atrial fibrillation and whose anti-thrombotic treatment cannot be withheld for vector injection or surgery).
- A history of hepatic cirrhosis or present hepatic dysfunction with total bilirubin > 2.0 mg/dL except for patients with Gilbert's syndrome who must have a direct bilirubin </= 1.0 mg/dL; AST/ALT >/= 2.5 times upper limit of normal.
- Renal insufficiency as determined by a serum creatinine > 2.0 mg/dL
- Patients may not have received prior therapy with chemotherapy, biologic therapy or radiation therapy for rectal cancer
- Significant history of a medical problem that would preclude the patient from undergoing an operative procedure such as a history of severe congestive heart failure or active ischemic heart disease
- Concurrent second malignancy requiring systemic therapy
- Pregnant or lactating women
- Chronic systemic corticosteroid use
- Prior surgery for rectal cancer
- Patients with history of deep venous thrombosis or pulmonary embolism
- Patients with Doppler evidence of deep venous thrombosis at screening
- Known history of documented coagulopathy or thrombophilic disorders
- Hormone replacement therapy within one month prior to Day 1
- Known history of documented cerebrovascular disease, stroke or transient ischemic attack (TIA)
- Surgery within the last one month, excluding diverting colostomy or ileostomy for obstruction
Contacts and Locations
More Information
Additional Information:
PubMed.gov 
No publications provided
| Responsible Party: | Paul Fischer, PhD, GenVec |
| ClinicalTrials.gov Identifier: | NCT00137878 History of Changes |
| Obsolete Identifiers: | NCT00069147, NCT00072241 |
| Other Study ID Numbers: | GV-001.007 |
| Study First Received: | August 26, 2005 |
| Last Updated: | February 22, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases |
ClinicalTrials.gov processed this record on May 16, 2013